Following my earlier post on this issue, it is now reported that the Indian Patent Office (IPO) has refused patent to the anti-cancer drug, Abraxane. I am yet to obtain a copy of this IPO order.
A recap
Briefly, the opposition against the patent application for Abraxane was filed by Natco Pharma with the IPO and was decided against the patent applicant, Abraxis Biosciences (“Abraxis”). Abraxis appealed against the IPO’s order with the Intellectual Property Appellate Board (IPAB) owing to certain procedural lapses. IPAB agreed with Abraxis and asked the IPO to consider the opposition afresh.
What’s new?
The recent order of the IPO is said to have stated the following:
“The amended claims (here Abraxis Boisciences) lack inventive step and do not constitute an invention under the Patents Act, 1970.”
I will update this post and discuss the IPO’s order in detail once I peruse the order.
Raja Selvam
Founder & Managing Attorney, Selvam & Selvam | Practice areas include Trademarks, Patents, Domain names & Business law. Visiting faculty, Department of Journalism, Madras University where I teach copyrights & trademarks law. Passionate about entrepreneurship, start-ups, stocks, farming, technology and law.
FIFA and Copyright: Online Piracy in India
There has been a lot of brouhaha over the recent judgment of the Delhi High Court, where the Court has ordered ISPs to block websites that were…
Trademark : One for all, all fight over one.
The Petitioner Sri Darshan Kumar started a partnership firm along with Sri Ranjit Kumar Sharma (Respondent) and Sri Raj Kumar in the year 2004. In…
Decoding software programmes and Copyrights in India
The other day I was just walking on the road trying to get somewhere when someone just handed me this pamphlet which stated that the coaching centre…